Related Experiment Video
Updated: Aug 13, 2026
11:17
Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
Growth hormone therapy update in Thailand
K Angsusingha1, S Watcharasindhu, S Likitmaskul
1Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Hormone Research
|April 29, 1998
Summary
Recombinant DNA human growth hormone (rhGH) therapy significantly improved height velocity in children with growth hormone deficiency (GHD) in Thailand. The treatment showed no adverse effects, indicating its safety and efficacy for pediatric GHD management.
Area of Science:
- Pediatrics
- Endocrinology
- Growth Disorders
Background:
- Growth hormone deficiency (GHD) affects numerous children globally.
- Idiopathic isolated GHD is a common diagnosis among pediatric patients.
- Limited access to recombinant DNA human growth hormone (rhGH) treatment in Thailand was observed.
Purpose of the Study:
- To evaluate the efficacy and safety of rhGH therapy in Thai children with GHD.
- To assess the impact of rhGH on height velocity and height standard deviation score (SDS).
Main Methods:
- A cohort of 30 GHD children received rhGH treatment for 1-2 years.
- Height velocity, bone age, and height SDS were monitored.
- Thyroid function and glycosylated hemoglobin levels were assessed.
Main Results:
- Statistically significant increases in height velocity were observed post-treatment (8.17+/-1.9 cm/year and 7.36+/-2.8 cm/year at 1 and 2 years, respectively) compared to pretreatment values (3.91+/-1.09 cm/year).
- Improved height SDS was noted at the end of each treatment period.
- No adverse effects or abnormalities in thyroid function or glycosylated hemoglobin were reported.
Conclusions:
- rhGH therapy is effective in improving linear growth in Thai children with GHD.
- The treatment is well-tolerated with a favorable safety profile.
- rhGH therapy offers a viable therapeutic option for pediatric GHD in the studied population.
Related Concept Videos
01:10Nature and Nurture
Many human characteristics, like height, are shaped by both nature—in other words, by our genes—and by nurture, or our environment. For example, chronic stress during childhood inhibits the production of growth hormones and consequently reduces bone growth and height. Scientists estimate that 70-90% of variation in height is due to genetic differences among individuals, and 10-30% of variation in height is due to differences in the environments that individuals experience, such as differences...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
01:21Satellite Stem Cells and Muscular Dystrophy
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:11Healing I: Introduction
Healing is the physiological process by which the body restores the integrity and function of damaged tissues following injury. It involves a coordinated interplay of cellular proliferation, extracellular matrix remodeling, and growth factor signaling. The extent and nature of the tissue damage determine whether healing occurs by resolution, regeneration, or replacement.ResolutionResolution represents the most complete form of healing, occurring when the injury is minimal and tissue...